Five Prime Therapeutics, Inc. (Nasdaq: FPRX) today announced that the European Commission has granted orphan designation for cabiralizumab (FPA008) for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE